Bacterial Vaginosis

Bacterial vaginosis (BV) is one of the most common vaginal conditions in adults, and a vaginal swab is the most accurate way to know whether you actually have it. Symptoms can be misleading. Roughly 50% to 84% of women with BV have no symptoms at all, while others experience odor or discharge that gets mistaken for a yeast infection and treated with the wrong medication.

This test looks at what is actually living in your vagina. A healthy result shows a community dominated by protective Lactobacillus bacteria. A BV result shows that those protective bacteria have been crowded out by a diverse mix of other organisms, which is linked to higher risks during pregnancy, more susceptibility to sexually transmitted infections, and ongoing inflammation in the genital tract.

What This Test Actually Measures

BV is not a single germ. It is a shift in the whole community of bacteria living in your vagina, sometimes called a microbiome imbalance (or dysbiosis). In a healthy state, Lactobacillus species (especially L. crispatus, L. jensenii, and L. gasseri) dominate and keep the environment acidic. In BV, those protective bacteria are reduced and replaced by a dense, diverse mix of anaerobic organisms (bacteria that thrive without oxygen), including Gardnerella, Atopobium (now called Fannyhessea), Prevotella, Megasphaera, and several others labeled BVAB-1, BVAB-2, and BVAB-3.

BV samples carry many more types of bacteria than a healthy vaginal microbiome and a much higher total bacterial load. Vaginal acidity drops (pH rises), and the lining of the vagina becomes more inflamed. Modern swab-based panels can quantify the specific organisms involved and classify your result as BV-positive, BV-negative, or in a transitional state where the community is shifting in one direction or the other.

Why Your Symptoms Are Not Enough

Clinical assessment based on symptoms and a basic in-clinic exam often misses BV. In a study comparing clinical diagnosis to a molecular vaginitis panel, positive agreement was only about 58%, meaning many women with BV were not identified. In that same study, 65% of BV cases and 44% of Candida cases detected by the assay were not treated based on clinical assessment alone.

Molecular swab tests consistently outperform clinical judgment. A large multicenter trial of the Aptima molecular swab assay reported about 95% sensitivity and 90% specificity for BV in clinician-collected samples. Another quantitative PCR panel reported about 93% sensitivity and 89% specificity compared with the Nugent score (the lab gold standard). A 22-species PCR test classifies samples within roughly 8 hours by looking at the relative amounts of Lactobacillus, Gardnerella, and BV-associated bacteria.

Pregnancy and Reproductive Outcomes

BV during pregnancy is linked to preterm birth, premature rupture of membranes, low birth weight, and intrauterine infection. In one prospective cohort in Bukavu, BV prevalence in pregnancy was 26.3% and was associated with adverse pregnancy outcomes including preterm birth and low birth weight. Among pregnant women in an Ethiopian antenatal clinic, prevalence was 22%, with rural residence and certain hygiene practices as factors. BV is also linked to pelvic inflammatory disease and recurrent pregnancy loss.

Current guidelines (USPSTF, ACOG, and CDC) do not recommend routine BV screening of asymptomatic pregnant women, and the USPSTF recommends against screening those not at increased risk for preterm delivery. If you are pregnant, trying to conceive, or planning a pregnancy soon, BV status can still be informative on a personal level, especially if you have symptoms or a history of BV. Among asymptomatic subfertile women, BV detected by PCR is common, and standard fertility workups do not screen for it directly.

HIV and Other Sexually Transmitted Infections

BV raises the risk of acquiring HIV and other sexually transmitted infections. BV has been linked to roughly a 60% increase in HIV acquisition risk. The mechanism involves both the loss of the protective acidic environment and an increase in immune cells in the vaginal lining that HIV preferentially targets. Research using vaginal swabs shows that BV is linked to dysfunctional T cells and altered immune signaling in the cervicovaginal tract, which together appear to enhance HIV susceptibility. Metronidazole treatment reduces those high-risk bacteria within days, with a corresponding drop in inflammatory markers.

BV also frequently co-occurs with HPV, chlamydia, gonorrhea, trichomonas, and yeast infections. In a large epidemiological review of over 2,100 women, an unbalanced vaginal ecosystem was strongly linked to increased risk of vaginitis, BV, and sexually transmitted diseases overall. If you are sexually active with new or multiple partners, BV status is part of the picture you want to see, not assume.

Inflammation and the Vaginal Lining

BV is not just a population shift. It actively damages the cells lining the vagina. Research shows that Gardnerella vaginalis can trigger programmed cell death (called apoptosis) in vaginal epithelial cells, increasing how many of those cells are shed and weakening the barrier. BV also raises inflammatory signaling molecules like IL-1 alpha and brings more monocytes and dendritic cells (immune cells) to the area. Treatment with metronidazole rapidly lowers these inflammatory markers, with the primary driver being the loss of BV bacteria rather than the expansion of lactobacilli.

Why One Reading Is Not Enough

The vaginal microbiome shifts. Recurrence after standard antibiotic treatment is common: ACOG reports recurrence in up to 30% of patients within 3 months and 58% within 12 months, and some reviews cite figures as high as 80% within a year. Bacterial communities can also move between healthy, transitional, and BV states in days. A single swab tells you where you are right now. A trend, when used thoughtfully, tells you whether your environment is stable, drifting toward dysbiosis, or recovering after treatment.

Major guidelines do not recommend routine periodic BV screening in asymptomatic people, and ACOG notes that follow-up rescreening is not necessary if symptoms have resolved after treatment. On a personal monitoring basis, a baseline swab can still be informative if you are sexually active, planning pregnancy, or have a history of BV. If your result is positive and you have been treated, retesting a few weeks after completing therapy can confirm resolution. Longitudinal swab and immune profiling shows that monocytes and specific signaling proteins (IP-10, MIG, ITAC) track BV status closely, suggesting that microbiome shifts can be caught before they become symptomatic.

Decision Pathway for a Positive Result

If your swab returns positive for BV and you have symptoms, the next step is targeted treatment. Standard first-line therapy is metronidazole or clindamycin. A follow-up swab a few weeks after treatment can confirm resolution if symptoms persist or return. If you are pregnant and have symptoms of BV, share the result with your obstetric provider so it can be treated. Routine screening and treatment of asymptomatic BV in pregnancy is not currently recommended by the CDC, ACOG, or USPSTF, so any decision to test or treat without symptoms should be made together with your clinician.

Order companion testing for chlamydia, gonorrhea, trichomoniasis, and yeast at the same visit, since BV often co-occurs with these infections and symptoms overlap. If you have had three or more BV episodes in a year, ask about a longer suppressive treatment plan (ACOG describes twice-weekly metronidazole gel for 16 weeks after the acute episode) and a follow-up plan that may include Lactobacillus-based products. One randomized trial of an oral Lactobacillus gasseri and Lactobacillus crispatus combination showed restored vaginal health in patients recovering from BV, though it did not improve cure rates on its own.

When Results Can Be Misleading

A few things distort a single swab result:

• Recent intercourse, douching, or vaginal products: semen, lubricants, spermicides, and douches can change vaginal acidity and bacterial counts. Wait at least 24 hours after intercourse and avoid douching for 48 hours before swabbing.
• Active menstrual bleeding: blood changes the microbial environment and can interfere with both molecular and Gram-stain interpretation. Test outside of your period when possible.
• Recent antibiotics: systemic antibiotics taken for any reason in the past 2 to 4 weeks can either temporarily improve or worsen BV markers without reflecting your normal baseline. After completing antibiotics for BV specifically, vaginal fungi (especially Candida) transiently increase for about a month before normalizing.
• Transitional states: some swabs show a mixed community that is neither clearly healthy nor clearly BV. This is a real biological state, not a lab error, and warrants a repeat swab in 2 to 4 weeks to see which direction the community is moving.

Specimen Collection Notes

Most BV vaginal swabs can be self-collected at home with results comparable to clinician-collected samples. In a study of 550 women in India, self-collected swabs showed at least 91% sensitivity and 100% specificity for BV, candidiasis, and trichomoniasis compared with physician-collected samples. A larger multicenter US trial found self- and clinician-collected swabs performed similarly on molecular panels.

For accurate self-collection: insert the swab roughly two inches into the vagina, rotate against the vaginal wall for about 10 to 15 seconds, and place it directly into the provided transport medium. Avoid touching the swab tip to anything else. Do not swab during heavy menstrual flow or within 24 hours of intercourse or douching.